PIF1 antibodies enable investigations into PIF1’s enzymatic activities, including:
Helicase Activity: PIF1’s 5′→3′ unwinding of RNA-DNA hybrids and G-quadruplex structures .
Post-Translational Modifications: Acetylation (e.g., K118, K129, K525) regulates its interaction with telomerase and DNA repair machinery .
Protein Interactions: Recruitment via RPA and PCNA to replication forks and DNA breaks .
| Antibody | Application | Key Finding | Source |
|---|---|---|---|
| sc-48377 (WB) | Telomerase inhibition | PIF1 displaces telomerase from DNA ends . | |
| ab192369 (WB) | PIF1 acetylation | Acetylation enhances helicase activity . |
Clear Cell Renal Carcinoma (ccRCC): High PIF1 expression correlates with advanced T/N/M stages, poor survival, and immune evasion .
ROC Analysis: PIF1 mRNA distinguishes ccRCC from normal tissues (AUC = 0.928) .
| Cancer Type | PIF1 Expression | Clinical Impact | Source |
|---|---|---|---|
| ccRCC | ↑ mRNA | Poor OS, DSS, PFI; linked to mitotic errors | |
| Lung/Cervical Cancer | Variable | PIF1 knockdown induces apoptosis . |
PIF1 antibodies are available in diverse formats to suit experimental needs:
Specificity: Polyclonal antibodies may cross-react with related helicases (e.g., Rrm3) .
Optimization: Dilutions vary (1:500–1:1000 for WB; 1:100–1:200 for IP) .
Thermophilic PIF1: Structural studies highlight conserved motifs but limited antibody reactivity .